For immunoprecipitation in the endogenous system, fully differentiated primary wild-type C57BL/6 BMDMs were seeded 24 h prior to stimulations. BMDMs were stimulated with LPS (100 ng/mL) alone, LPS + TAK1-inhibitor (5Z-7-oxozeaenol [0.1 μM]) or LPS + TAK1-inhibior + zVAD (30 mM). After 4 h of stimulation, BMDMs were lysed in NP-40 lysis buffer. Whole cell lysates were harvested and incubated with 3 mg of indicated primary antibodies overnight at 4°C. Protein A/G plus agarose beads were added to these samples and incubated at 4°C for another 2 h. Agarose beads were centrifuged and washed in NP-40 lysis buffer three times, and immunoprecipitates were eluted by adding sample buffer. Immunoprecipitates in sample buffer were then subjected to immunoblotting analysis.
Immunoprecipitation of NLRP3, ZBP1, RIPK3, and RIPK1
For immunoprecipitation in the endogenous system, fully differentiated primary wild-type C57BL/6 BMDMs were seeded 24 h prior to stimulations. BMDMs were stimulated with LPS (100 ng/mL) alone, LPS + TAK1-inhibitor (5Z-7-oxozeaenol [0.1 μM]) or LPS + TAK1-inhibior + zVAD (30 mM). After 4 h of stimulation, BMDMs were lysed in NP-40 lysis buffer. Whole cell lysates were harvested and incubated with 3 mg of indicated primary antibodies overnight at 4°C. Protein A/G plus agarose beads were added to these samples and incubated at 4°C for another 2 h. Agarose beads were centrifuged and washed in NP-40 lysis buffer three times, and immunoprecipitates were eluted by adding sample buffer. Immunoprecipitates in sample buffer were then subjected to immunoblotting analysis.
Corresponding Organization : St. Jude Children's Research Hospital
Protocol cited in 7 other protocols
Variable analysis
- Overexpression of pcDNA3-N-FLAG-NLRP3, RIPK3-GFP, pCMV-mRIPK1, or pcDNA-mCherry-ZBP1 expression plasmids
- Co-transfection of pCMV6-mASC-turboGFP, pCDH-CMV-CASP8, pcDNA3-N-FLAG-NLRP3, RIPK3-GFP, pCMV-mRIPK1, and pcDNA-mCherry-ZBP1 expression plasmids
- Stimulation of primary wild-type C57BL/6 BMDMs with LPS alone, LPS + TAK1-inhibitor (5Z-7-oxozeaenol [0.1 μM]), or LPS + TAK1-inhibior + zVAD (30 mM)
- Immunoprecipitation of NLRP3, ZBP1, RIPK3, or RIPK1
- Immunoprecipitation of the complex by RIPK3
- Immunoblotting analysis of immunoprecipitates
- Use of pan-caspase inhibitor zVAD-fmk to inhibit cell death due to overexpression
- Fully differentiated primary wild-type C57BL/6 BMDMs used as the endogenous system
- Positive control: Not explicitly mentioned
- Negative control: Not explicitly mentioned
Annotations
Based on most similar protocols
As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!